Trial
NCT04781374
Neratinib in Patients With Metastatic Castration-Resistant Prostate Cancer
Phase IIWITHDRAWNOPERATIONALConfidence: HIGH
Sponsor
Beth Israel Deaconess Medical Center
Collaborators
Puma Biotechnology, Inc.; Dana-Farber Cancer Institute
Condition
Metastatic Prostate Adenocarcinoma
Intervention
Neratinib
Why stopped
Withdrawal of funding
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2023-07-11